Eli Lilly's experimental drug retatrutide showed greater reduction in A1C and double the average weight loss in a head-to-head clinical study against Ozempic.
This article was originally published by 9News Colorado (RSS) on Wednesday, October 28, 2026. TownPost surfaces local news from over 40 outlets and uses AI to score each story for relevance to Longmont and the surrounding area.
Relevance score: 20/100. This story has regional context that may affect Longmont.
TownPost does not modify or rewrite source content. Read the full article at its original publication for complete coverage.
